Ortho RTi Expands Scientific Advisory Board with Appointment of Accomplished Orthopedic Surgeon, Dr. Jacques Toueg
KIRKLAND, QC, Dec. 19, 2017 /CNW Telbec/ - Ortho Regenerative Technologies Inc. (CSE: ORTH.CN) ("Ortho RTi" or the "Corporation"), an emerging Orthopaedic and Sports Medicine Technology company, today announced that Dr. Jacques Toueg has been appointed to its Scientific Advisory Board ("SAB').
Dr. Toueg, a practicing Orthopedic Surgeon and Director of the Montreal Institute for Special Surgery, specializes in sports medicine and in arthroscopic surgery of the shoulder and knee. He is the chief medical officer of la coupe Rogers's Cup and the National Tennis training center in Montreal. Dr. Toueg has treated numerous athletes from national teams, professional boxers, as well as a number of players from the National Hockey League, the Major Junior Hockey League of Quebec and the Canadian Football League. Since 2010, he has co-hosted the Radio-Canada program, The Doctors.
Dr. Toueg received his B.Sc. in physiotherapy from McGill University, his M.D. from Universite de Montreal and completed a fellowship in Sports Medicine and Arthroscopic Surgery at the University of British Columbia.
"On behalf of everyone at Ortho RTi, I would like to welcome Jacques to our team," said the Corporation's Executive Chairman and CEO, Dr. Brent Norton. "He joins Ortho RTi's SAB at a time where the sports medicine community is increasingly recognizing the potential of our Ortho-R hybrid implants to offer surgeons and patients the ability to actually fix soft tissue injuries instead of just treating the often-devastating complications associated with them. Jacque's strong clinical and research experience, combined with his extensive network of contacts in both amateur and professional sports, should prove to be a tremendous asset."
In connection with Dr. Toueg's appointment to Ortho RTi's SAB, and pursuant the Corporation's stock option plan, the Board of Directors of the Corporation has granted Dr. Toueg 100,000 stock options (the "Options"), exercisable at $0.50 per share. The Options will vest 25% per year and once vested are exercisable for five years from the date of grant.
About Ortho Regenerative Technologies Inc.
Ortho RTi is an emerging Orthopaedic and Sports Medicine technology company dedicated to the development of novel therapeutic tissue repair technology to dramatically improve the success rate of sports medicine surgeries for soft tissue injuries. Our proprietary biopolymer has been specifically designed to increase the healing rates of injuries to tendons, meniscus and cartilage. The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Visit us on the internet at www.orthorti.com.
Forward-Looking Statements
This news release may contain certain forward-looking statements regarding the Corporation's expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Corporation disclaims any intention or obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.
SOURCE Ortho Regenerative Technologies Inc.
For further information: Stephen Kilmer, Investor & Media Relations, 647.872.4849, [email protected]
Share this article